Search clinical trials for: AZD9574

Total 71 results

AstraZeneca

Completed

A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers

Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca
Quintiles, Inc.

Completed

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

Healthy

United States
National Cancer Institute (NCI)

Completed

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
AstraZeneca

Completed

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

Relapsed/Refractory Peripheral T-cell Lymphoma | Relapsed/Refractory Classical Hodgkins Lymphoma

Italy, Sweden, United States, Taiwan, Korea, Republic of, United Kingdom, Australia, France, Singapore
AstraZeneca

Completed

Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

Renal Impairment

United States
AstraZeneca

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | High Risk Myelodysplastic Syndrome | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma | Richter's Syndrome | T-cell Non-Hodgkin Lymphoma | Relapsed or Refractory...

United Kingdom, Germany, Netherlands
AstraZeneca
Parexel

Completed

A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
AstraZeneca

Completed

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

Cancer | Advanced Solid Malignancies

Japan
AstraZeneca

Recruiting

Study of AZD0754 in Participants With Metastatic Prostate Cancer (APOLLO)

Metastatic Prostate Cancer

United States, Australia
AstraZeneca

Terminated

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Cancer | Advanced Solid Malignancies

United States, Italy, United Kingdom, France, Germany, Spain, Netherlands
AstraZeneca
Parexel

Completed

A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects

Healthy Volunteers

United Kingdom
AstraZeneca
Quotient Sciences

Completed

Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects

Cardiovascular Disease

United Kingdom
AstraZeneca

Recruiting

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

Hepatic Impairment

United States
AstraZeneca

Not yet recruiting

LTFU for All Cell and Gene Therapy Studies (LOCUS)

Hepatocellular Carcinoma | Prostate Cancer

United States
AstraZeneca

Completed

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

Healthy

United States
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Urothelial Carcinoma

China
AstraZeneca

Withdrawn

Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion

Healthy

United States
AstraZeneca

Terminated

A Single and Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Japanese Subjects (JSMAD)

Healthy

United Kingdom
AstraZeneca

Completed

AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects

Healthy

United States
AstraZeneca

Completed

A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects

Heart Failure

United Kingdom
AstraZeneca

Completed

AZD9773 Dose Escalation Study

Severe Sepsis

United States
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Pharmacokinetics | Safety | Pharmacodynamics of AZD7594

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Asthma

United States, Germany, South Africa, Ukraine, Japan, Hungary, Poland, Bulgaria
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males

Healthy Subjects | Pharmacokinetics | Tolerability | Safety

United Kingdom
Abbisko Therapeutics Co, Ltd

Completed

ABSK091 Food Effect Study in Healthy Subjects

Health, Subjective | Food-drug Interaction

Taiwan
AstraZeneca

Completed

A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock

Septic Shock | Severe Sepsis

Czech Republic, France, Spain, Finland, Canada, Australia, Belgium
AstraZeneca

Completed

An Open Label Prostate Cancer Study in Japanese Patients

Prostate Cancer

Japan
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma

Asthma

United States
AstraZeneca

Completed

Open Label Prostate Cancer Study

Prostate Cancer

United Kingdom, Netherlands, United States
AstraZeneca

Completed

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca
Parexel

Completed

A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.

Asthma

Germany
AstraZeneca

Terminated

A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease

Healthy | COPD

Sweden
AstraZeneca
Parexel

Completed

Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects

Healthy Volunteers

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration

Heart Failure

United Kingdom
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.

Rheumatoid Arthritis

Germany, United Kingdom
AstraZeneca

Recruiting

A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese (CONTEMPO)

Non-alcoholic Steatohepatitis (NASH)

Austria, Germany, Japan, Sweden
AstraZeneca
Parexel

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

Non-alcoholic Steatohepatitis

United Kingdom
AstraZeneca

Completed

A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

Asthma | Efficacy | Safety

Germany, Bulgaria
AstraZeneca

Completed

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

Healthy | Elderly | Tolerability

United States
AstraZeneca

Completed

AZD9164 Single Ascending Dose Study in Healthy Male Subjects

Healthy

Sweden
AstraZeneca

Completed

A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock

Septic Shock | Severe Sepsis

Japan
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene Amplification

United States, Canada
University of Chicago
National Cancer Institute (NCI)

Completed

Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

Precancerous Condition | Lip and Oral Cavity Squamous Cell Carcinoma | Oral Cavity Verrucous Carcinoma

United States
AstraZeneca

Completed

A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects

Healthy Subjects | Pharmacodynamics

United Kingdom
AstraZeneca

Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)

Advanced Solid Malignancies

United States, Korea, Republic of, Spain, Australia, Sweden, Germany, United Kingdom
AstraZeneca

Completed

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease (MIRACLE)

Heart Failure | Chronic Kidney Disease

United States, Germany, Italy, Spain, Belgium, Denmark, Thailand, Poland, Canada, Korea, Republic of, Slovakia, Taiwan, Turkey, Ukraine, Japan, Czechia, Hungary, Bulgaria, Russian Federation, Sweden, Lithuania, India
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Urothelial Carcinoma

China
AstraZeneca

Terminated

Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer (SHINE)

Gastric Cancer | Gastro-oesophageal Junction Cancer

Bulgaria, Czech Republic, Italy, Korea, Republic of, Spain, United Kingdom, Hungary, Romania, Ukraine, Belgium, Canada, Germany, Taiwan, India, Japan, France

3

Subscribe